Once the tumor becomes resistant to castration (mCRPC), therapy options include chemotherapy, radiotherapy and prostate specific membrane antigen (PSMA)-directed treatment (Cornford et al. 2017). This evidence concerns the gene FOLH1 and neoplasm.